Current Report Filing (8-k)
April 01 2022 - 01:35PM
Edgar (US Regulatory)
0000890821 false 0000890821 2022-03-31
2022-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
March 31, 2022
ENVERIC BIOSCIENCES, INC.
(Exact
name of Registrant as specified in its charter)
|
Delaware |
|
001-38286 |
|
95-4484725 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
No.)
|
|
(IRS
Employer
Identification
No.)
|
Enveric
Biosciences, Inc.
4851 Tamiami Trail N,
Suite 200
Naples,
FL
34103
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code:
(239)
302-1707
(Former
name or former address, if changed since last
report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
| |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common stock, par value $0.01 per share |
|
ENVB |
|
The Nasdaq Stock Market |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
On
March 31, 2022, Enveric Biosciences, Inc. issued a press release
announcing its financial results for the fiscal year ended December
31, 2021. A copy of this press release is furnished as Exhibit 99.1
hereto and is incorporated herein by reference.
In
accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, that is furnished pursuant to this Item 2.02 shall not be
deemed to be “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, and shall
not be incorporated by reference into any registration statement or
other document filed under the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly set forth by
specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
ENVERIC BIOSCIENCES INC. |
|
|
|
|
|
Date:
April 1, 2022 |
By: |
/s/
Joseph Tucker |
| |
|
Joseph
Tucker |
| |
|
Chief
Executive Officer |
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Feb 2023 to Mar 2023
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Mar 2022 to Mar 2023
